Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumonia. (11th July 2022)

• Record Type: Journal Article
• Authors: Dreesen, Erwin; Gijsen, Matthias; Elkayal, Omar; Annaert, Pieter; Debaveye, Yves; Wauters, Joost; Karlsson, Mats O; Spriet, Isabel
• Is Part Of: Journal of antimicrobial chemotherapy. Volume 77:Number 9(2022)
• Page Start: 2479
• Page End: 2488
• Publication Date: 2022-07-11
• Subjects: Anti-infective agents -- Periodicals; Chemotherapy -- Periodicals; 615.58
• DOI: 10.1093/jac/dkac209
• Languages: English
• ISSNs: 0305-7453

Abstract

Abstract: Objectives: PTA of protein-unbound ceftriaxone may be compromised in critically ill patients with community-acquired pneumonia (CAP) with augmented renal clearance (ARC). We aimed to determine an optimized ceftriaxone dosage regimen based on the probability of developing ARC on the next day ( P ARC, d+1 ; www.arcpredictor.com ). Patients and methods: Thirty-three patients enrolled in a prospective cohort study were admitted to the ICU with severe CAP and treated with ceftriaxone 2 g once daily. Patients contributed 259 total ceftriaxone concentrations, collected during 1 or 2 days (±7 samples/day). Unbound fractions of ceftriaxone were determined in all peak and trough samples ( n = 76). Population pharmacokinetic modelling and simulation were performed using NONMEM7.4. Target attainment was defined as an unbound ceftriaxone concentration >4 mg/L throughout the dosing interval. Results: A two-compartment population pharmacokinetic model described the data well. The maximal protein-bound ceftriaxone concentration decreased with lower serum albumin. Ceftriaxone clearance increased with body weight and P ARC, d+1 determined on the previous day. A high P ARC, d+1 was identified as a clinically relevant predictor for underexposure on the next day (area under the receiver operating characteristics curve 0.77). Body weight had a weak predictive value and was therefore considered clinically irrelevant. Serum albumin had no predictive value. An optimal P ARC, d+1 threshold of 5.7% was identified (sensitivity 73%, specificity 69%). Stratified once- or twice-daily 2 g dosing when below or above the 5.7% P ARC, d+1 cut-off, respectively, was predicted to result in 81% PTA compared with 47% PTA under population-level once-daily 2 g dosing. Conclusions: Critically ill patients with CAP with a high P ARC, d+1 may benefit from twice-daily 2 g ceftriaxone dosing for achieving adequate exposure on the next day.